Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype

Therapeutic Drug Monitoring

Volumn 36, Issue 1, 2014, Pages 80-85

  Hendset, Magnhild ^a   Molden, Espen ^a,b   Knape, Magnus ^a,b   Hermann, Monica ^a,b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

aripiprazole; CYP2D6 genotype; intermediate metabolizers; risperidone; steady state serum concentrations; therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; PALIPERIDONE; RISPERIDONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERMEDIATE METABOLIZER PHENOTYPE; MAJOR CLINICAL STUDY; MENTAL PATIENT; MIDDLE AGED; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIPSYCHOTIC AGENTS; CHILD; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; RISPERIDONE; YOUNG ADULT;

EID: 84892938608     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000018     Document Type: Article

References (32)

1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
2. Mulder H, Heerdink ER, van Iersel EE, et al. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study. Ann Pharmacother. 2007;41:408-413.
3. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689-723.
4. Web site of the human cytochrome P450 (CYP) allele nomenclature committee. Available at: http://medicine.iupui.edu/clinpharm/ddis/clinicaltable/ . Accessed October 25, 2013.
5. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
6. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
7. Stingl JC, Brockmoller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013;18:273-287.
8. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-243.
9. Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G.A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76:128-138.
10. Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496-526.
11. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
12. Yasui-Furukori N, Mihara K, Kondo T, et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol. 2003;43:122-127.
13. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005;20:55-64.
14. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48:761-804.
15. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999;147:300-305.
16. Hendset M, Molden E, Refsum H, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009;29:537-541.
17. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57:671-675.
18. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol. 2007;63:1147-1151.
19. Suzuki T, Mihara K, Nakamura A, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2011;33:21-24.
20. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. Published 2007. Available at: http://medicine.iupui.edu/clinpharm/ddis/clinical-table/. Accessed October 25, 2013.
21. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28:744-749.
22. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry. 1993;38(suppl 3):S80-S88.
23. Sparshatt A, Taylor D, PatelMX, et al. A systematic review of aripiprazoledose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71: 1447-1456.
24. Tod M, Goutelle S, Gagnieu MC. Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther. 2011;90:582-587.
25. Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39:121-127.
26. Voicu VA, de Leon J, Medvedovici AV, et al. New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs. Eur Neuropsychopharmacol. 2012;22:319-329.
27. de Leon J, Susce MT, Johnson M, et al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr. 2009;14:19-34.
28. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37.
29. Barclay ML, Sawyers SM, Begg EJ, et al. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics. 2003;13:627-632.
30. Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics. 2002;12:465-472.
31. Laika B, Leucht S, Heres S, et al. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 2009;9: 395-403.
32. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem. 2004;50:1623-1633.